15110 Federal Register / Vol. 77, No. 50 / Wednesday, March 14, 2012 / Notices 

1 (67 FR 76603). 

2Public Law 106–102, 113 Stat. 1338 (1999). 

Estimated Annual reporting hours: 

100 hours. 

Estimated average hours per response: 

Loan participation renewal notice, 2 

hours; Acquisition notice, 6 hours; 

Internal corporate reorganization 

transactions notice, 6 hours; and Section 

23A additional exemption notice, 10 

hours. 

Number of respondents: Loan 

participation renewal notice, 1; 

Acquisition notice, 1; Internal corporate 

reorganization transactions notice, 12; 

and Section 23A additional exemption 

notice, 2. 

General description of report: This 

information collection is required to 

evidence compliance with sections 23A 

and 23B of the Federal Reserve Act (12 

U.S.C. 371c and 371c-1). Confidential 

and proprietary information collected 

for the purposes of the Loan 

Participation Renewal notice (12 CFR 

223.15(b)(4)) may be protected under 

the authority of section (b)(4) of FOIA [5 

U.S.C. 552(b)(4)]. That section of FOIA 

exempts commercial or financial 

information deemed competitively 

sensitive from disclosure. Respondents 

who desire that the information on this 

notice be kept confidential in 

accordance with section (b)(4) can 

request confidential treatment under the 

Board’s rules at 12 CFR 261.15. In 

addition, information that is obtained as 

part of an examination of a financial 

institution is exempt from disclosure 

under exemption (b)(8) of FOIA. 5 

U.S.C. 552(b)(8). 

Abstract: On December 12, 2002, the 

Federal Reserve published a Federal 

Register notice 1 adopting Regulation W 

(Reg W) to implement sections 23A and 

23B. Reg W was effective April 1, 2003. 

The Board issued Reg W for several 

reasons. First, the regulatory framework 

established by the Gramm-Leach-Bliley 

Act 2 emphasized the importance of 

sections 23A and 23B as a means to 

protect depository institutions from 

losses in transactions with affiliates. 

Second, adoption of a comprehensive 

rule simplified the interpretation and 

application of sections 23A and 23B, 

ensured that the statute is consistently 

interpreted and applied, and minimized 

burden on banking organizations to the 

extent consistent with the statute’s 

goals. Third, issuing a comprehensive 

rule allowed the public an opportunity 

to comment on Federal Reserve 

interpretations of sections 23A and 23B. 

The information collection 

requirements associated with Regulation 

W comprise four notices: (1) The Loan 

Participation Renewal notice (12 CFR 

223.15(b)(4)), which is a condition to an 

exemption for renewals of loan 

participations involving problem loans; 

(2) the Acquisition notice (12 CFR 

223.31(d)(4)), which is a condition to an 

exemption for a depository institution’s 

acquisition of an affiliate that becomes 

an operating subsidiary of the 

institution after the acquisition; (3) the 

Internal Corporate Reorganization 

Transactions notice (12 CFR 

223.41(d)(2)),which is a condition to an 

exemption for internal corporate 

reorganization transactions; and (4) the 

Section 23A Additional Exemption 

notice (12 CFR 223.43(b)),which 

provides procedures for requesting 

additional exemptions from the 

requirements of section 23A. These 

notifications are event-generated and 

must be provided to the appropriate 

federal banking agency and, if 

applicable, the Federal Reserve Board 

within the time periods established by 

the law and regulation. 

Board of Governors of the Federal Reserve 

System, March 8, 2012. 

Jennifer J. Johnson, 

Secretary of the Board. 

[FR Doc. 2012–6074 Filed 3–13–12; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications will also be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than April 9, 2012. 

A. Federal Reserve Bank of Richmond 

(Adam M. Drimer, Assistant Vice 

President) 701 East Byrd Street, 

Richmond, Virginia 23261–4528: 

1. First Carolina Financial Services, 

Inc., Durham, North Carolina; to become 

a bank holding company by acquiring at 

least 95 percent of the voting shares of 

First Carolina State Bank, Rocky Mount, 

North Carolina, and Pisgah Community 

Bank, Asheville, North Carolina. 

Board of Governors of the Federal Reserve 

System, March 9, 2012. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 2012–6147 Filed 3–13–12; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2012–N–0218] 

Antiviral Drugs Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Antiviral Drugs 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

DATES: Date and Time: The meeting will 

be held on May 10, 2012, from 8 a.m. 

to 5:30 p.m. 

ADDRESSES: FDA is opening a docket for 

public comment on this meeting. The 

docket number is FDA–2012–N–0218. 

The docket will open for public 

comment on March 14, 2012. The 

docket will close on May 17, 2012. 

Interested persons may submit either 

electronic or written comments 

regarding this meeting. Submit 

electronic comments to http:// 

www.regulations.gov. Submit written 

comments to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 


srobinson on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 50 / Wednesday, March 14, 2012 / Notices 15111 

comments received will be posted 

without change, including any personal 

information provided. It is only 

necessary to send one set of comments. 

Identify comments with the docket 

number found in brackets in the 

heading of this document. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

Comments received on or before April 

26, 2012, will be provided to the 

committee before the meeting. 

Location: FDA White Oak Campus, 

10903 New Hampshire Ave., Building 

31 Conference Center, the Great Room 

(rm. 1503), Silver Spring, MD 20993– 

0002. Information regarding special 

accommodations due to a disability, 

visitor parking, and transportation may 

be accessed at: http://www.fda.gov/ 

AdvisoryCommittees/default.htm; under 

the heading ‘‘Resources for You,’’ click 

on ‘‘Public Meetings at the FDA White 

Oak Campus.’’ Please note that visitors 

to the White Oak Campus must enter 

through Building 1. 

Contact Person: Yvette Waples, Center 

for Drug Evaluation and Research, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, FAX: 301–847–8533, email: 

AVAC@fda.hhs.gov, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), and follow the 

prompts to the desired center or product 

area. Please call the Information Line for 

up-to-date information on this meeting. 

A notice in the Federal Register about 

last minute modifications that impact a 

previously announced advisory 

committee meeting cannot always be 

published quickly enough to provide 

timely notice. Therefore, you should 

always check the Agency’s Web site and 

call the appropriate advisory committee 

hot line/phone line to learn about 

possible modifications before coming to 

the meeting. 

Agenda: The committee will discuss 

an efficacy supplement for new drug 

application (NDA) 21–572, TRUVADA 

(emtricitabine/tenofovir disoproxil 

fumarate) Tablet, submitted by Gilead 

Sciences, Inc. The supplemental 

application proposes an indication for 

Pre-Exposure Prophylaxis (PrEP) to 

reduce the risk of sexually acquired 

HIV–1 infection. 

FDA intends to make background 

materials available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. All electronic and 

written submissions submitted to the 

Docket (see the ADDRESSES section of 

this document) on or before April 26, 

2012, will be provided to the committee. 

Oral presentations from the public will 

be scheduled between approximately 2 

p.m. and 3 p.m. Those individuals 

interested in making formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before April 18, 

2012. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by April 19, 2012. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Yvette 

Waples at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: March 8, 2012. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2012–6115 Filed 3–13–12; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Proposed Collection: 

Comment Request 

In compliance with the requirement 

for opportunity for public comment on 

proposed data collection projects 

(section 3506(c)(2)(A) of Title 44, United 

States Code, as amended by the 

Paperwork Reduction Act of 1995, Pub. 

L. 104–13), the Health Resources and 

Services Administration (HRSA) 

publishes periodic summaries of 

proposed projects being developed for 

submission to the Office of Management 

and Budget (OMB) under the Paperwork 

Reduction Act of 1995. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and draft instruments, email 

paperwork@hrsa.gov or call the HRSA 

Reports Clearance Officer at (301) 443– 

1984. 

Comments are invited on: (a) The 

proposed collection of information for 

the proper performance of the functions 

of the agency; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. 

Proposed Project: Voluntary Partner 

Surveys To Implement Executive Order 

12862 in the Health Resources and 

Services Administration—(OMB No. 

0915–0212)—[Revision] 

In response to Executive Order 12862, 

the Health Resources and Services 

Administration (HRSA) is proposing to 

conduct voluntary customer surveys of 

its partners to assess strengths and 

weaknesses in program services and 

processes. HRSA partners are typically 

State or local governments, health care 

facilities, health care consortia, health 

care providers, and researchers. HRSA 

is requesting a generic approval from 

OMB to conduct the partner surveys. 


srobinson on DSK4SPTVN1PROD with NOTICES